🎄Merry Christmas and Season's greetings from Mursla Bio🌟

Excited to join #JPM24 in San Francisco, presenting Mursla Bio Bio's innovative work. We're discussing AI-enhanced liver cancer tests and breakthroughs in Extracellular Vesicles. Our focus: integrating EV multi-omics and AI for advanced healthcare solutions. Grateful for this

🌟 NEW PAPER ALERT: Breakthrough liquid biopsy publication in Cell🌟 Excited to share that our liquid biopsy tech is featured in iScience! 🎉 Our paper, "An electro-optical platform for ultrasensitive detection of small extracellular vesicle sub-types," showcases our

🚀 Mursla Bio Expands to the US with New Office in Cambridge, MA! 🚀 We are thrilled to announce our expansion into the US market with a new office in Cambridge, Massachusetts! This marks a major step in transforming cancer diagnosis and treatment through our novel liquid biopsy

October is Liver Cancer Awareness Month – a time when we come together to raise awareness and take action against one of the fastest-growing causes of cancer-related deaths. At Mursla Bio, this mission is deeply personal to us. We are committed to transforming liver cancer

Our Founder & CEO Pierre Arsène spoke with the influential lifescience trade publication The Medicine Maker as part of the prediction’s series, “The Multifaceted Future of Pharma”. For the second piece in the series, Pierre discusses the upcoming clinical translation of

🚨 EvoLiver™: Setting a New Standard in Liver Cancer Surveillance 🚨 At the AASLD Liver Meeting 2024, we unveiled exciting results from our multi-centre MEV01 study. EvoLiver™, our dynamic biopsy-based blood test, achieved 86% early-stage sensitivity and 88% specificity,

𝐓𝐡𝐞 𝐋𝐢𝐯𝐞𝐫 𝐌𝐞𝐞𝐭𝐢𝐧𝐠: Mursla Bio presented data suggesting that its EvoLiver diagnostic test can spot liver cancer among cirrhotic patients with 86% early-stage sensitivity and 88% specificity. #TLM24 Full video: biotechtv.com/post/mursla-bi…

BioCentury's latest Emerging Company Profile features Mursla Bio, which is using extracellular vesicles to detect cancer. Led by ex-banker Pierre Arsène, the company's first goal is surveillance of cirrhosis patients at risk of liver cancer buff.ly/3PDLQ78

🎉 We are thrilled to share that Mursla Bio has been shortlisted for TWO awards at the 2025 Cambridge Independent (Cambridge Independent) Science and Technology Awards – The Award for Innovation and MedTech Company of the Year! Being recognised in Cambridge—one of the most vibrant and

We are delighted to welcome Dr Raquel Sanches-Kuiper as Head of Research & Development at Mursla Bio. Raquel brings over 20 years of leadership experience in diagnostics, genomics and assay development, having most recently served as VP Science & Applications at Evonetix. There,

We are proud to announce that EvoLiver™, Mursla Bio’s flagship test for liver cancer surveillance, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). The FDA awards Breakthrough Device Designation to a select number of medical

HCC Surveillance 2.0: FDA Recognizes Mursla Bio’s Extracellular Vesicle Test EvoLiver's U.S. FDA Breakthrough Device designation could swing liver #cancer surveillance tests from ultrasound to blood-based. hubs.li/Q03jWGXS0

Last week our FDA Breakthrough Device Designation announcement was the most-read article on GenomeWeb and 360Dx – two of the most respected publications in the genomics and diagnostics space. This recognition reflects the growing momentum around our mission to change the

🧠 Introducing the Mursla Bio AI Precision Medicine Platform Mursla Bio is proud to announce the launch of its AI Precision Medicine Platform, a full-stack solution enabling organ-specific, multi-omic analysis from blood to advance precision diagnostics and patient

Researchers are turning to a new approach for early cancer detection, making use of nanoscale biological structures called extracellular vesicles. trib.al/UPXmuUq

🧬 Mursla Bio was recently featured in a new article by STAT , as a leading company that’s supporting the shift to extracellular vesicles (EVs) for early cancer detection. The article explains why many experts are looking beyond DNA-based blood tests. DNA is often present